JP2011037889A5 - - Google Patents

Download PDF

Info

Publication number
JP2011037889A5
JP2011037889A5 JP2010232130A JP2010232130A JP2011037889A5 JP 2011037889 A5 JP2011037889 A5 JP 2011037889A5 JP 2010232130 A JP2010232130 A JP 2010232130A JP 2010232130 A JP2010232130 A JP 2010232130A JP 2011037889 A5 JP2011037889 A5 JP 2011037889A5
Authority
JP
Japan
Prior art keywords
phospholipid
block copolymer
derived
amount
surface modifier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010232130A
Other languages
English (en)
Japanese (ja)
Other versions
JP5539839B2 (ja
JP2011037889A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011037889A publication Critical patent/JP2011037889A/ja
Publication of JP2011037889A5 publication Critical patent/JP2011037889A5/ja
Application granted granted Critical
Publication of JP5539839B2 publication Critical patent/JP5539839B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2010232130A 1998-03-30 2010-10-15 水不溶性物質のマイクロ粒子を製造するための組成物及び方法 Expired - Fee Related JP5539839B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7980998P 1998-03-30 1998-03-30
US60/079,809 1998-03-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000540812A Division JP4709378B2 (ja) 1998-03-30 1999-03-29 水不溶性物質のマイクロ粒子を製造するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2011037889A JP2011037889A (ja) 2011-02-24
JP2011037889A5 true JP2011037889A5 (https=) 2012-08-30
JP5539839B2 JP5539839B2 (ja) 2014-07-02

Family

ID=22152962

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000540812A Expired - Fee Related JP4709378B2 (ja) 1998-03-30 1999-03-29 水不溶性物質のマイクロ粒子を製造するための組成物及び方法
JP2010232130A Expired - Fee Related JP5539839B2 (ja) 1998-03-30 2010-10-15 水不溶性物質のマイクロ粒子を製造するための組成物及び方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000540812A Expired - Fee Related JP4709378B2 (ja) 1998-03-30 1999-03-29 水不溶性物質のマイクロ粒子を製造するための組成物及び方法

Country Status (14)

Country Link
US (1) US6387409B1 (https=)
EP (1) EP1067914B1 (https=)
JP (2) JP4709378B2 (https=)
KR (1) KR100628341B1 (https=)
CN (1) CN1303278B (https=)
AT (1) ATE318132T1 (https=)
AU (1) AU761205B2 (https=)
CA (1) CA2326456C (https=)
DE (1) DE69929959T2 (https=)
ES (1) ES2257041T3 (https=)
IL (3) IL162023A0 (https=)
SE (1) SE0003429L (https=)
TW (1) TWI267383B (https=)
WO (1) WO1999049846A2 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7255877B2 (en) 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
ATE318132T1 (de) * 1998-03-30 2006-03-15 Jagotec Ag Zubereitungen enthaltend mikropartikel von wasserunlöslichen substanzen, sowie verfahren zu deren herstellung
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
KR100635456B1 (ko) 1998-05-29 2006-10-18 스키에파마 캐나다 인코포레이티드 열보호화 마이크로입자 조성물 및 그의 말단의 스팀멸균방법
IL143197A0 (en) 1998-11-20 2002-04-21 Rtp Pharma Inc Dispersible phospholipid stabilized microparticles
WO2000030615A1 (en) * 1998-11-20 2000-06-02 Rtp Pharma Inc. Method of preparing stable suspensions of insoluble microparticles
AU7984200A (en) * 1999-09-21 2001-04-24 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
BR0212833A (pt) 2001-09-26 2004-10-13 Baxter Int Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
EP1492511B3 (fr) 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
FR2842736B1 (fr) 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
CN1243538C (zh) * 2002-11-21 2006-03-01 武汉利元亨药物技术有限公司 熊果酸豆磷脂纳米粒冻干粉针及制备方法
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US6931888B2 (en) 2003-02-07 2005-08-23 Ferro Corporation Lyophilization method and apparatus for producing particles
US20040178135A1 (en) * 2003-03-13 2004-09-16 Beplate Douglas K. Filtering device incorporating nanoparticles
CA2524538A1 (en) * 2003-05-19 2004-12-02 Baxter International Inc. Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers
JP2007509981A (ja) * 2003-10-31 2007-04-19 テバ ファーマシューティカル インダストリーズ リミティド 薬物デリバリー用ナノ粒子
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
DE602005011928D1 (de) 2004-01-20 2009-02-05 Allergan Inc Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure
US20050170063A1 (en) * 2004-01-29 2005-08-04 Lalit Chordia Production of powder and viscous material
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
WO2006017347A2 (en) * 2004-07-12 2006-02-16 Allergan, Inc. Opthalmic compositions and methods for treating ophthalmic conditions
WO2006043965A1 (en) * 2004-10-14 2006-04-27 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
EP1815869A4 (en) * 2004-11-24 2011-04-06 Nanocarrier Co Ltd PROCESS FOR CHANGING THE MORPHOLOGY OF BLOCK COPOLYMERS
WO2006138202A2 (en) * 2005-06-14 2006-12-28 Baxter International Inc. Pharmaceutical formulations for minimizing drug-drug interactions
WO2007008697A2 (en) * 2005-07-08 2007-01-18 University Of Chicago Compositions and methods for refolding of denatured proteins
US20070134341A1 (en) * 2005-11-15 2007-06-14 Kipp James E Compositions of lipoxygenase inhibitors
WO2008080047A2 (en) * 2006-12-23 2008-07-03 Baxter International Inc. Magnetic separation of fine particles from compositions
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
SI2170279T1 (en) * 2007-07-31 2018-04-30 Otsuka Pharmaceutical Co., Ltd. Methods for producing aripiprazole suspension and freeze-dried formulation
EP2200613B1 (en) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
AU2011320159B2 (en) * 2010-10-29 2016-12-22 Western University Of Health Sciences Ternary mixture formulations
WO2014004507A1 (en) * 2012-06-27 2014-01-03 Shell Oil Company Fuel and engine oil composition and its use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091187A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
MX9201782A (es) 1991-04-19 1992-10-01 Sandoz Ag Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene.
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5326552A (en) 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
EP0808154B1 (en) * 1995-02-06 2000-12-20 Elan Pharma International Limited Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
ATE386506T1 (de) * 1995-10-17 2008-03-15 Jagotec Ag Verabreichung unlöslicher arzneistoffe
US5686133A (en) 1996-01-31 1997-11-11 Port Systems, L.L.C. Water soluble pharmaceutical coating and method for producing coated pharmaceuticals
WO1998007414A1 (en) * 1996-08-22 1998-02-26 Research Triangle Pharmaceuticals Ltd. Compositions comprising microparticles of water-insoluble substances and method for preparing same
WO1999029300A1 (en) * 1997-12-10 1999-06-17 Rtp Pharma Inc. Self-emulsifying fenofibrate formulations
ATE318132T1 (de) * 1998-03-30 2006-03-15 Jagotec Ag Zubereitungen enthaltend mikropartikel von wasserunlöslichen substanzen, sowie verfahren zu deren herstellung
WO2013047199A1 (ja) * 2011-09-30 2013-04-04 Jx日鉱日石金属株式会社 スパッタリングターゲット及びその製造方法

Similar Documents

Publication Publication Date Title
JP2011037889A5 (https=)
JP2002509876A5 (https=)
Salzano et al. Self-assembly nanoparticles for the delivery of bisphosphonates into tumors
JP6427097B2 (ja) 癌を処置するための組成物および該組成物を製造するための方法
Gao et al. Polymeric capsule-cushioned leukocyte cell membrane vesicles as a biomimetic delivery platform
JP2014532665A5 (https=)
KR102650691B1 (ko) 폴리락트산염을 포함하는 약물전달용 나노입자 조성물 제조용 키트
US20200009050A1 (en) Pharmaceutical composition, preparation and uses thereof
CN114096274A (zh) 免疫治疗构建体以及其使用方法
HRP20230655T1 (hr) Metode liječenja artritisa
FI3603620T3 (fi) Liposomikoostumus ja farmaseuttinen koostumus
JP2010512384A5 (https=)
JP2017517533A5 (https=)
JP6893245B2 (ja) 脂質ナノ粒子用膜材料組成物
CA2854430C (en) Liposomal corticosteroids for treatment of inflammatory disorders in humans
JPWO2020071349A1 (ja) 薬物を内包するリポソーム組成物およびプラチナ製剤を含む組合せ医薬
JP2022064923A (ja) 癌を治療するための方法および組成物
ES2645076T3 (es) Adyuvante
US20230310504A1 (en) Platelet membrane coated nanoparticles and uses thereof
TW202015703A (zh) 包含內含吉西他濱之脂質體組成物及免疫檢查點抑制劑之組合醫藥
CA3150972A1 (en) Immune stimulating micelle composition
CN117377467A (zh) 用于制备含有药物且不含两亲聚合物的纳米颗粒的试剂盒
HRP20230985T1 (hr) Farmaceutske formulacije pegiliranih liposoma i faktora koagulacije krvi
Gonsalves et al. University of Rhode Island, 7 Greenhouse Road, Kingston, RI 02881 Email: jmenon@ uri. edu Tel: 401-874-4914
US20240358639A1 (en) Nanoparticles for cancer treatment